First-in-Human trial tests engineered immune cells against tough pancreatic cancer
NCT ID NCT06158139
Summary
This early-stage study is testing the safety of a new cell therapy for pancreatic cancer that has come back after standard treatment. Doctors modify a patient's own immune cells (called CAR-T cells) to target a protein found on pancreatic cancer cells. The main goal is to find a safe dose and understand side effects in about 27 adults with advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.